141 related articles for article (PubMed ID: 27785782)
1. Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.
Bari A; Marcheselli L; Marcheselli R; Pozzi S; Cox MC; Baldessari C; Ferri P; Gobbi P; Baldini L; Tadmor T; Musto P; Federico M; Sacchi S
Br J Haematol; 2018 Feb; 180(4):600-602. PubMed ID: 27785782
[No Abstract] [Full Text] [Related]
2. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
Kostakoglu L; Evens AM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
[TBL] [Abstract][Full Text] [Related]
5. Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.
Tadmor T; Bari A; Marcheselli L; Sacchi S; Aviv A; Baldini L; Gobbi PG; Pozzi S; Ferri P; Cox MC; Cascavilla N; Iannitto E; Federico M; Polliack A
Mayo Clin Proc; 2015 Jun; 90(6):756-64. PubMed ID: 26046410
[TBL] [Abstract][Full Text] [Related]
6. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
7. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
8. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M; Eigtved AI; Specht L
Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.
Porrata LF; Ristow K; Colgan JP; Habermann TM; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
Haematologica; 2012 Feb; 97(2):262-9. PubMed ID: 21993683
[TBL] [Abstract][Full Text] [Related]
11. Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma.
Simon Z; Barna S; Miltenyi Z; Husi K; Magyari F; Jona A; Garai I; Nagy Z; Ujj G; Szerafin L; Illes A
Int J Hematol; 2016 Jan; 103(1):63-9. PubMed ID: 26462809
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
13. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
Romano A; Parrinello NL; Vetro C; Forte S; Chiarenza A; Figuera A; Motta G; Palumbo GA; Ippolito M; Consoli U; Di Raimondo F
Br J Haematol; 2015 Mar; 168(5):689-700. PubMed ID: 25376846
[TBL] [Abstract][Full Text] [Related]
14. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
15. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?
Zijlstra JM; Burggraaff CN; Kersten MJ; Barrington SF;
Haematologica; 2016 Nov; 101(11):1279-1283. PubMed ID: 27799345
[No Abstract] [Full Text] [Related]
17. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
[TBL] [Abstract][Full Text] [Related]
18. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
Reddy JP; Hernandez M; Gunther JR; Dabaja BS; Martin GV; Jiang W; Akhtari M; Allen PK; Atkinson BJ; Smith GL; Pinnix CC; Milgrom SA; Abou Yehia Z; Osborne EM; Oki Y; Lee H; Hagemeister F; Fanale MA
Br J Haematol; 2018 Feb; 180(4):545-549. PubMed ID: 29271057
[TBL] [Abstract][Full Text] [Related]
19. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma.
Kobe C; Dietlein M; Fuchs M
Leuk Lymphoma; 2010 Mar; 51(3):552-3. PubMed ID: 20141443
[No Abstract] [Full Text] [Related]
20. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
